Key takeaways
- • Frequency: Common — 10-14% in trials.
- • Trial reference: STEP-1 (semaglutide) (10-14%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Multiple mechanisms: dehydration from reduced food/fluid intake, blood-sugar changes, and possible direct GLP-1 receptor effect in vasculature.
How to manage it
- Hydrate aggressively: 64-100 oz water daily, more in hot weather
- Eat regularly even when not hungry — small protein-rich snacks prevent blood-sugar drops
- OTC analgesics (acetaminophen, ibuprofen) generally safe — caution with NSAIDs if kidney concerns
- Reduce caffeine if you suddenly cut it (withdrawal headaches mimic GLP-1 headaches)
- Track patterns — peak nausea + dose increase often correlate with headache
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Sudden severe "worst headache of life" — emergency
- • Headache + neurological symptoms (vision changes, weakness, numbness)
- • Headache + fever + neck stiffness
- • Persistent headache lasting >7 days
Drug-specific notes
- Wegovy: Headache ~14% at peak
- Mounjaro: Headache ~10% reported
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Gastrointestinal
Gallbladder issues on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)